Stratipath and PathAI Partner to Expand Access to AI-based Precision Diagnostics
Stratipath Breast will be available within PathAI’s AISight® Dx Image Management System (IMS)
Stratipath and Visiopharm partner to advance implementation of AI-Powered Breast Cancer Diagnostics
Stratipath and Visiopharm, today announced a strategic collaboration to combine their regulatory compliant solutions for enhanced breast cancer diagnostics.
Region Östergötland Implements AI-Powered Stratipath Breast to Enhance Breast Cancer Diagnostics
Linköping University Hospital and Region Östergötland have chosen to implement Stratipath Breast as part of their clinical routine for early breast cancer diagnostics.
Region Uppsala chooses to implement AI-based risk profiling with Stratipath Breast
Region Uppsala, Sweden’s fourth largest healthcare region, has chosen to implement Stratipath Breast, an AI-based risk profiling solution for breast cancer, in clinical use.
Stratipath releases biopsy capability for its CE-IVD marked AI diagnostic solution, Stratipath Breast
Stratipath releases biopsy capability for its CE-IVD marked AI diagnostic solution, Stratipath Breast. The new capability strengthens clinical decision-making for neoadjuvant therapy.
Diagnexia and Stratipath Partner to Expand AI-Based Cancer Precision Diagnostics Across the UK and Europe
Diagnexia, and Stratipath AB are pleased to announce a strategic partnership. This collaboration will bring Stratipath Breast, an AI-based prognostic risk profiling tool for invasive breast cancer, to pathology laboratories, hospitals, and healthcare providers across the UK and Europe.
Professor Daniel Hayes Joins Stratipath’s Scientific Advisory Board
Stratipath is proud to announce that globally recognized breast oncologist, Professor Daniel F. Hayes, has joined the company’s Scientific Advisory Board. Professor Hayes will collaborate closely with the board, chaired by Professor Jonas Bergh, to further advance Stratipath’s innovative solutions in breast cancer precision diagnostics.
Unilabs is implementing Stratipath Breast for enhanced breast cancer diagnostics at Capio S:t Göran’s Hospital
Capio St Göran’s Hospital is one of the largest breast cancer clinics in Sweden treating more than 600 breast cancer patients annually. With this new collaboration, Unilabs will use Stratipath Breast on a selected group of these patients.
Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics
Stratipath is thrilled to announce a collaboration with Roche, the world’s largest biotechnology company and the global leader in in-vitro diagnostics.
A new validation study on the prognostic performance of Stratipath Breast.
Stratipath is excited to announce the publication of a new validation study on the prognostic performance of Stratipath Breast—the first AI-based CE-marked medical device for risk stratification of breast cancer using routine H&E histopathology images.